Table 2.
Details of final diagnosis of all SELs (n = 130).
| Disease, n (%) | No. | ||
|---|---|---|---|
| Total | Surgical | Nonsurgical | |
| n = 130 | n = 72 | n = 58 | |
| GIST | 68 (52.3) | 55 (76.4) | 13 (22.4) |
| Leiomyoma | 10 (7.7) | 3 (4.2) | 7 (12.1) |
| Carcinoma | 10 (7.7) | 5 (6.9) | 5 (8.6) |
| Schwannoma | 6 (4.6) | 3 (4.2) | 3 (5.2) |
| Sarcoma | 3 (2.3) | 0 | 3 (5.2) |
| NEN | 2 (1.5) | 1 (1.4) | 1 (1.7) |
| Aberrant pancreas | 2 (1.5) | 0 | 2 (3.4) |
| Hematoma | 2 (1.5) | 2 (2.8) | 0 |
| Lymph node | 2 (1.5) | 0 | 2 (3.4) |
| Inflammatory granuloma | 1 (0.8) | 1 (1.4) | 0 |
| MALT lymphoma | 1 (0.8) | 0 | 1 (1.7) |
| MPS | 1 (0.8) | 0 | 1 (1.7) |
| Gastritis | 1 (0.8) | 0 | 1 (1.7) |
| Hyperplasia | 1 (0.8) | 1 (1.4) | 0 |
| Lipoma | 1 (0.8) | 1 (1.4) | 0 |
| Non-diagnosis | 19 (14.6) | 0 | 19 (32.8) |
SELs, subepithelial lesions; GIST, gastrointestinal stromal tumor; NEN, neuroendocrine neoplasm; MALT lymphoma, mucosa-associated lymphoid tissue lymphoma; MPS, mucosal prolapse syndrome.